Human IgG1 Kappa Isotype Control - Deruxtecan DAR4

Human

Hen Egg Lysozyme

Human IgG1

ICH3001

Blue ice

Robust antibody-drug-conjugate research depends on matched, non-targeting controls that mirror the conjugation chemistry of test articles. This human IgG1 kappa isotype control is directed against hen egg lysozyme, an antigen absent from mammalian systems, so it provides no specific binding and serves as a clean negative control. Conjugated with deruxtecan at a drug-to-antibody ratio of 4 (DAR4), it lets researchers account for payload, linker and DAR effects independent of target engagement when setting background and gating in functional studies. Supplied in a low-endotoxin format suitable for in vivo use and produced in scalable milligram (mg) to gram (g) quantities, it is a research-use-only reagent for high-throughput and bulk ADC work.

PBS, pH 7.4, Contains no stabilizers or preservatives. 0.2 μM filtered

The product should be stored in the original stock concentration at 4°C. Avoid freeze / thaw cycles.

Research Use Only. Not for Therapeutic or Diagnostic Use

Q: What is the Deruxtecan DAR4 isotype control used for?

A: It is a non-targeting Human IgG1 Kappa antibody-drug conjugate that binds only Hen Egg Lysozyme, providing a payload- and format-matched negative control for targeted ADC studies.

Q: Is this ADC isotype control in vivo grade and low endotoxin?

A: Yes, it is supplied as a low-endotoxin, in vivo-grade preparation suitable for matched control arms in preclinical and in vivo experiments (RUO).

Q: Why match the DAR4 drug-to-antibody ratio in a control?

A: Using a control with the same payload and conjugation ratio isolates target-specific effects from payload- and linker-related background in ADC experiments.